rozanolixizumab   Click here for help

GtoPdb Ligand ID: 9801

Synonyms: CA170_01519.g57 IgG4P | rozanolixizumab-noli | Rystiggo® | UCB-7665 | UCB7665
Approved drug Immunopharmacology Ligand
rozanolixizumab is an approved drug (FDA (2023))
Compound class: Antibody
Comment: Rozanolixizumab is an anti-human FcRn monoclonal antibody that is being developed for potential use in the treatment of IgG-driven autoimmune diseases [1,3-4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Fc fragment of IgG receptor and transporter Hs Antibody Binding ~8.2 – 8.7 pKd - 1
⤷ pKd ~8.2 – 8.7 (Kd ~6x10-9 – 2x10-9 M) [1]
Description: In a cell- based in vitro assay using neutral buffer. Note this affinity range is for the 01519.g57 Fab or PEGylated Fab fragment, not the intact IgG4P antibody.